| 10/13/2026 7:40 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/25/2026 3:30 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 3:30 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/13/2026 9:55 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/06/2026 10:55 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/02/2026 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 07/31/2026 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 3:16 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/30/2026 3:05 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3/A | |
| 07/22/2026 7:37 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NRSNW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/25/2026 8:25 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 3:30 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 3:30 PM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 8:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 9:13 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/08/2026 8:05 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 2:38 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/06/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/03/2026 8:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 3:25 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/01/2026 3:26 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:16 PM | Mandil-Levin Revital (2125058) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 7:49 AM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/30/2026 7:51 AM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/24/2026 9:11 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 2:35 PM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Leuchtenberger Mark (1303315) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Golan Roy (1999257) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | Claiborne Cary J (1370930) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | NeuroSense Therapeutics (1875091) Issuer Tracik Ferenc (2120172) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 11:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/11/2026 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/18/2026 8:21 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 4:28 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 01/06/2026 4:27 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 10:49 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
I have publicly predicted six major American crashes, before each one happened. (Ad) Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit.
Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. See Martin Weiss's full warning before this risk spreads further |
| 12/08/2025 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 7:39 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B3 | |
| 11/25/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 11/21/2025 5:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 3:26 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |